Eye (uveal) melanomas are rare and behave differently to common skin melanomas. Until this year there were no established drug treatments for people with metastatic uveal melanoma.
In February 2021 a novel drug, tebentafusp, became the first approved drug treatment for patients with advanced uveal melanoma. The approval was granted following a successful Phase 3 trial that showed tebentafusp was better able extend life in adults with newly diagnosed uveal melanoma than existing therapies.
Tebentafusp is now available in Australia
Tebentafusp is now available in Australia through a compassionate access program. To find out more contact us via the ARC Portal at email@example.com or give us a call at +61 (3) 9342 2690
Email UsCall Us